Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing
NCT06907797 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 75
Last updated 2026-05-20
Summary
This study aims to test the Tools for Reducing Inequity in Acute Leukemia (TRIAL) web-based application that is designed to support participants with acute leukemia by providing information and resources about leukemia and clinical trial participation.
Conditions
Interventions
- BEHAVIORAL
-
TRIAL Web-Based Application
A web-based application that provides disease and trial education and access to resources provided by the Leukemia and Lymphoma Society (LLS). iPads will be provided to participants for 14 days.
Sponsors & Collaborators
-
American Society of Clinical Oncology
collaborator OTHER -
National Cancer Institute (NCI)
collaborator NIH - lead OTHER
Principal Investigators
-
Andrew Hantel, MD · Dana-Farber Cancer Institute
Study Design
- Allocation
- NA
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-04-01
- Primary Completion
- 2027-05-01
- Completion
- 2027-06-30
Countries
- United States
Study Locations
More Related Trials
-
Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia
NCT01649791 ·Status: TERMINATED ·Phase: NA
-
Studying Biomarkers in Cell Samples From Young Patients With Acute Myeloid Leukemia
NCT01057290 ·Status: COMPLETED
-
Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia
NCT00006097 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia
NCT00703300 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy of Intermediate and High Intensity Regimens in Patients With Relapsed Acute Lymphoblastic Leukemia
NCT04699162 ·Status: COMPLETED
-
Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia
NCT00003861 ·Status: ACTIVE_NOT_RECRUITING
-
506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
NCT00004239 ·Status: TERMINATED ·Phase: PHASE1
-
A Study in Participants With Acute Leukemia
NCT01214603 ·Status: COMPLETED ·Phase: PHASE2
-
Quality of Life Study for Adult Patients With Acute Lymphoblastic Leukemia
NCT01148927 ·Status: COMPLETED
-
Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00039377 ·Status: COMPLETED ·Phase: PHASE2
-
Real-World Disease Management and Outcomes in Chronic Myeloid Leukaemia
NCT05893836 ·Status: COMPLETED
-
Biomarkers in Samples From Patients With B-Cell Acute Lymphoblastic Leukemia
NCT01505699 ·Status: COMPLETED
-
Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia
NCT01003769 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia
NCT00459212 ·Status: COMPLETED ·Phase: PHASE1
-
Gemcitabine in Treating Patients With Recurrent Chronic Lymphocytic Leukemia
NCT00005829 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD
NCT05137860 ·Status: UNKNOWN ·Phase: PHASE4
-
A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults
NCT02611492 ·Status: RECRUITING ·Phase: PHASE3
-
Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia
NCT00053144 ·Status: COMPLETED ·Phase: PHASE1
-
Studying Biomarkers in Samples From Younger Patients With Acute Myeloid Leukemia
NCT01642121 ·Status: COMPLETED
-
Multiple Myeloma/Chronic Lymphocytic Leukemia Coach RCT
NCT05928156 ·Status: COMPLETED ·Phase: NA
-
Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leukémia(ALL) Adults Stage III
NCT00483132 ·Status: COMPLETED ·Phase: PHASE3
-
Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia
NCT01670084 ·Status: WITHDRAWN ·Phase: PHASE2
-
Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia
NCT01861314 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence
NCT05310591 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Molecular Genetic Lesions and Clinical Outcomes in Children With Acute Lymphoblastic Leukemia
NCT00003291 ·Status: COMPLETED